Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for review its biologics license application for zeleciment rostudirsen (z‑rostudirsen, also known as DYNE‑251) to treat individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. The FDA granted Priority Review and set a Prescription Drug User Fee Act target action date of January 21, 2027.
The company stated it continues to expect a potential U.S. launch of z‑rostudirsen in the first quarter of 2027, assuming approval is received on this anticipated timeline. Dyne also emphasized that these expectations are forward‑looking and subject to substantial risks and uncertainties, including clinical, regulatory and financing factors described in its SEC reports.
Dyne Therapeutics, Inc. director-affiliated venture funds completed open-market sales of a combined 777,451 shares of common stock on July 6–7, 2026. The trades, at weighted-average prices between about $22.79 and $23.62 per share, were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026.
The shares were sold by Atlas-managed funds, including Atlas Venture Fund XI and Atlas Venture Opportunity Funds, in which director Jason P. Rhodes participates through general partner entities. He disclaims Section 16 beneficial ownership beyond any pecuniary interest. After the transactions, these funds continue to hold multimillion-share positions, such as 2,962 shares in one Atlas vehicle.
Dyne Therapeutics, Inc. director Jason P. Rhodes reported that investment entities associated with him sold a total of 504,695 shares of common stock in open-market transactions on June 26 and June 29, 2026.
The shares were sold at weighted-average prices around $21.14–$21.28, within disclosed ranges from $21.00 up to $21.61, under a Rule 10b5-1 trading plan adopted on March 19, 2026. The transactions were executed by Atlas Venture and related funds, and Rhodes disclaims Section 16 beneficial ownership of these securities except to the extent of his pecuniary interest. Following the sales, individual Atlas-affiliated entities continue to report sizeable indirect holdings, including 4,579,456 and 1,396,475 shares of Dyne Therapeutics common stock.